Cml Healthcare Inc news

   Watch this stock
Showing stories 1 - 10 of about 27   

Articles published

CLC 0.0000
price chart
Glencore female director marks progress for mining
Mining companies, long laggards in appointing women to their boards, are starting to catch up under pressure from corporate governance groups and activist shareholders.
Glencore's Female Director Marks Mining Industry Progress
... began her career in the mid-1970s working for Marc Lalonde, Canada's Minister for the Status of Women. Lalonde later become finance minister.
Related articles »  
DIARY - UK and Irish Corporate events from Jul 1,2014
THOMSON REUTERS , Diary of UK and Irish Corporate events For full list of companies reporting each day click on First Financial Holdings Inc For a full list of all Western European Corp events, click on For a full list of major european corp events ...
Related articles »  
The High Cost of Second-Generation TKIs for CML is an Obstacle to Effective ...
Preferred first- and second-line treatments: While Glivec is the preferred first-line treatment for CML in both countries; Sprycel is the preferred second-line treatment, strongly ahead of Tasigna, which is likely a reflection of Tasigna's lack of ...
Related articles »  
Glencore female director marks progress
More recently, she has been the chairwoman of CML Healthcare, an Ontario-based diagnostic services provider. In that role, she shepherded through last year's $1.1bn takeover by Lifelabs Medical Laboratory Services.
Related articles »  
Novartis cancer patient access program lauded
A patient support group has lauded Novartis Healthcare Philippines for its unprecedented access program that helps poor patients get the cancer treatments they need.
Novartis maintained strong innovation momentum in second quarter, while ...
(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook .
Novartis AG: Novartis maintained strong innovation momentum in second ...  The Wall Street Transcript
Related articles »  
The Fight Against Cancer Just Took an Innovative Turn
The arrival on the market of the drug Gleevec in 2001, for instance, revolutionized the battle against leukemia (CML), a disease that used to be highly lethal.
Related articles »  
Trillium Therapeutics: An Preclinical Cancer Immunotherapy Company With A ...
In December 2013, Trillium Therapeutics raised $33M from a private placement with prominent US healthcare funds, which is expected to fund SIRPαFc through IND-enabling studies, manufacturing, and Phase 1 clinical.
Novartis introduces new anti-malarial formulation, Coartem 80/480 in Kenya
Novartis has launched a new high quality antimalarial formulation of Coartem 80/480 (artemether/lumefantrine 80 mg/480 mg), for the treatment of uncomplicated malaria in adults and older children who weigh above 35kg.